GLP-1 Drugs and COVID-19 Outcomes
Obesity is a significant risk factor for severe COVID-19 outcomes, including hospitalization, intensive care admission, and death. By treating obesity, GLP-1 drugs may reduce the risk of severe COVID-19 in people with obesity. Studies published during the pandemic showed that people with obesity who lost weight before COVID-19 infection had better outcomes than those who did not. Retatrutide, as the most effective weight loss drug ever tested, could theoretically provide the largest risk reduction.
Direct Effects of GLP-1 on COVID-19
Beyond the indirect effect of weight loss, GLP-1 receptor activation has anti-inflammatory effects that could theoretically be beneficial in COVID-19, where excessive inflammation drives severe disease. A 2023 study in Diabetes Care found that people with type 2 diabetes taking GLP-1 drugs had lower rates of severe COVID-19 outcomes than those taking other diabetes medications, even after adjusting for weight and other risk factors. No retatrutide-specific COVID-19 data exists, but the class effect suggests potential benefit rather than risk.
Leave a Reply